Fulgent Genetics Inc

Research Fulgent Genetics Inc (FLGT) on Bullrun: market cap USD 548.92M. Explore financials, valuation history, model signals, and stock context.

Key Metrics

Valuation Snapshot

latest market cap is USD 548.92M.

Five-year financial history

YearRevenueNet incomeFree cash flowGross marginDiluted EPSCashTotal debtEquity
FY2025USD 322.67M-USD 60.51M-USD 124.21M40.6%-1.96USD 50.19MUSD 7.68MUSD 1.11B
FY2024USD 283.47M-USD 42.71M-USD 19.26M37.8%-1.41USD 55.14MUSD 8.47MUSD 1.13B
FY2023USD 289.21M-USD 167.83MUSD 4.80M36.1%-5.64USD 97.47MUSD 15.25MUSD 1.14B
FY2022USD 618.97MUSD 143.40MUSD 234.75M59.3%n/aUSD 79.51MUSD 20.79MUSD 1.27B

Valuation history

YearSnapshot dateMarket capP/EDividend yieldAnnual dividend/share
20262026-08-25USD 548.92Mn/an/an/a
20252025-12-31USD 816.50Mn/an/an/a
20242024-12-31USD 569.63Mn/an/an/a
20232023-12-29USD 856.69Mn/an/an/a
20222022-12-30USD 900.10M3.4n/an/a
20212021-12-31USD 3.03B6.1n/an/a

About Fulgent Genetics Inc

Fulgent Genetics, Inc. provides clinical diagnostic and therapeutic development solutions to physicians and patients in the United States and internationally. The company's clinical diagnostic solutions include molecular diagnostic testing; genetic testing; anatomic pathology laboratory tests and testing services, such as gastrointestinal pathology, dermatopathology, urologic pathology, breast pathology, neuropathology, and hematopathology; oncology tests and testing services;

Related stock research

Other Healthcare stocks

Frequently asked questions

What is Fulgent Genetics Inc's market cap?

Fulgent Genetics Inc's market capitalization is USD 548.92M.

What does Fulgent Genetics Inc do?

Fulgent Genetics, Inc. provides clinical diagnostic and therapeutic development solutions to physicians and patients in the United States and internationally. The company's clinical diagnostic solutions include molecular diagnostic testing; genetic testing; anatomic pathology laboratory tests and testing services, such as gastrointestinal pathology, dermatopathology, urologic pathology, breast pathology, neuropathology, and hematopathology; oncology tests and testing services; and sequencer services related to hereditary cancer, reproductive health, and other diseases.